Page last updated: 2024-12-11

jasplakinolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R*,4E,6S*,8R*)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9831636
CHEMBL ID257166
CHEBI ID66104
SCHEMBL ID62754
MeSH IDM0160941

Synonyms (22)

Synonym
cyclo[(3r)-3-(4-hydroxyphenyl)-.beta.-alanyl-(2s,6r,8s)- 8-hydroxy-2,4,6-trimethyl-4-nonenoyl-l-alanyl-2-bromo- n-methyl-d-tryptophyl]
nsc-613009
mls002702908 ,
jaspamide
.beta.-alanine,4,6-trimethyl- 1-oxo-4-nonenyl)-l-alanyl]-n-methyl-d-tryptophyl]- 3-(4-hydroxyphenyl)-, .rho.-lactone,[2s-[1(s*),2r*,4e,6s*,8r*]]-
jasplakinolide
c36h45brn4o6
beta-alanine, n-(2-bromo-n-(n-(8-hydroxy-2,4,6-trimethyl-1-oxo-4-nonenyl)-l-alanyl)-n-methyl-d-tryptophyl)-l-3-(4-hydroxyphenyl)-, p-lactone, (2s-(2r*,4e,6s*,8r*))-
CHEMBL257166
chebi:66104 ,
C16883
(4r,7r,10s,13s,15e,17r,19s)-7-[(2-bromo-1h-indol-3-yl)methyl]-4-(4-hydroxyphenyl)-8,10,13,15,17,19-hexamethyl-1-oxa-5,8,11-triazacyclononadec-15-ene-2,6,9,12-tetrone
SCHEMBL62754
AKOS024457296
cyclo[(3r)-3-(4-hydroxyphenyl)-?-alanyl-(2s,4e,6r,8s)-8-hydroxy-2,4,6-trimethyl-4-nonenoyl-l-alanyl-2-bromo-n-methyl-d-tryptophyl]
HB3946
jasplakinolide, >=97% (hplc)
DTXSID30893487
Q27134619
HY-P0027
CS-0012978
(3s,6r,9r,13s,15r,16e,19s)-3,5,13,15,17,19-hexamethyl-6-[(2-bromo-1h-indole-3-yl)methyl]-9-(4-hydroxyphenyl)-12-oxa-2,5,8-triazacyclononadeca-16-ene-1,4,7,11-tetraone

Research Excerpts

Overview

Jasplakinolide is a reagent that stabilizes and polymerizes actin filaments and is a commonly used tool in cell biology. It is a potential candidate for further preclinical development and a lead structure for a novel class of therapeutic agents.

ExcerptReferenceRelevance
"Jasplakinolide is a sponge toxin that stabilizes and rigidifies microfilaments."( Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo.
Fondy, TP; Hatfield, S; Trendowski, M; Wellington, K; Wong, V,
)
1.11
"Jasplakinolide is a reagent that stabilizes and polymerizes actin filaments and is a commonly used tool in cell biology. "( The actin-specific reagent jasplakinolide induces apoptosis in primary rat parotid acinar cells.
Fujita-Yoshigaki, J; Hashimoto, S; Matsuki-Fukushima, M; Murakami, M; Narita, T; Ogata, Y; Sugiya, H, 2012
)
2.12
"Jasplakinolide is a potential candidate for further preclinical development and a lead structure for a novel class of therapeutic agents that can disrupt the actin cytoskeleton in mammalian cells."( Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
Crews, P; Grever, MR; Inman, WD; Kaur, G; Laing, C; Malspeis, L; Rodríguez, J; Sainz, E; Sausville, EA; Senderowicz, AM, 1995
)
3.18
"Jasplakinolide is a member of a new class of antitumor agents targeting the actin cytoskeleton with activity against prostate cancer. "( Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.
Duncan, LK; Duncan, MD; Harmon, JW, 1996
)
1.74
"Jasplakinolide is a novel natural product anticancer agent which acts by inducing overpolymerization of actin. "( Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
Ara, G; Sausville, EA; Takeuchi, H; Teicher, B, 1998
)
3.19
"Jasplakinolide is an interesting new anticancer agent for which further study both as an anticancer agent and in combined modality regimens is warranted."( Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
Ara, G; Sausville, EA; Takeuchi, H; Teicher, B, 1998
)
3.19
"Jasplakinolide is a cyclodepsipeptide which represents a new class of antifungal agents with potent activity against Candida albicans. "( New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species.
Boehme, R; Matthews, TR; Scott, VR, 1988
)
2

Actions

ExcerptReferenceRelevance
"Jasplakinolide did not inhibit changes in intracellular Ca(2+) seen after fMLP treatment, or inhibit neutrophil immobilisation induced by externally added Mn(2+)."( Role of the cytoskeleton in rapid activation of CD11b/CD18 function and its subsequent downregulation in neutrophils.
Anderson, SI; Hotchin, NA; Nash, GB, 2000
)
1.03

Treatment

Jasplakinolide treatment caused a dose-dependent increase in cell-cell fusion as measured by both syncytia and reporter gene assays. Treatment with jasplarinolide or latrunculin A partially rescued a fusion pore opening defect caused by deletion of the PIV5 F protein cytoplasmic tail.

ExcerptReferenceRelevance
"Jasplakinolide treatment decreases proliferation of MDA-MB-231 cells in both dose and time dependent manner. "( Jasplakinolide Attenuates Cell Migration by Impeding Alpha-1-syntrophin Protein Phosphorylation in Breast Cancer Cells.
Ali, R; Bhat, SS; Hamid, R; Khanday, FA; Mir, HA; Shah, RA, 2021
)
3.51
"Jasplakinolide treatment caused a dose-dependent increase in cell-cell fusion as measured by both syncytia and reporter gene assays, and latrunculin A treatment also resulted in fusion stimulation."( The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cell-cell fusion.
Dutch, RE; McCann, RO; Moncman, CL; Schowalter, RM; Smith, EC; Wurth, MA, 2010
)
1.08
"Jasplakinolide-treated cells were still motile; however, their rate of movement was less than that of untreated cells."( Formation of F-actin aggregates in cells treated with actin stabilizing drugs.
Knecht, DA; Lee, E; Shelden, EA, 1998
)
1.02
"Jasplakinolide-treated tachyzoites were unable to invade host cells, but once the drug was removed the parasites were able to enter host cells."( Induction of an acrosomal process in Toxoplasma gondii: visualization of actin filaments in a protozoan parasite.
Shaw, MK; Tilney, LG, 1999
)
1.02
"Treatment with jasplakinolide or latrunculin A partially rescued a fusion pore opening defect caused by deletion of the PIV5 F protein cytoplasmic tail, but these drugs had no effect on fusion inhibited at earlier stages by either temperature arrest or by a PIV5 heptad repeat peptide."( The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cell-cell fusion.
Dutch, RE; McCann, RO; Moncman, CL; Schowalter, RM; Smith, EC; Wurth, MA, 2010
)
0.7
"Pretreatment with jasplakinolide, an actin polymerizing agent, or a myosin heavy chain IIA (MHCIIA) blocker, blebbistatin, inhibited glucose-induced CD38 internalization, an essential step for cADPR formation."( Involvement of actin filament in the generation of Ca2+ mobilizing messengers in glucose-induced Ca2+ signaling in pancreatic β-cells.
Higashida, C; Higashida, H; Kim, BJ; Kim, UH; Park, KH; Shawl, AI,
)
0.45
"Pretreatment with jasplakinolide also blocked de novo expression of integrin CD11b and shape change which otherwise occurred in minutes after treatment with fMLP."( Actin polymerisation regulates integrin-mediated adhesion as well as rigidity of neutrophils.
Gratzer, WB; Nash, GB; Pinder, JC; Sheikh, S, 1997
)
0.62
"If treated with jasplakinolide after fMLP, the cells stopped migrating but could not detach when fMLP was removed."( Role of the cytoskeleton in rapid activation of CD11b/CD18 function and its subsequent downregulation in neutrophils.
Anderson, SI; Hotchin, NA; Nash, GB, 2000
)
0.64

Toxicity

ExcerptReferenceRelevance
" Taken together with previous patch clamp data, our findings suggest that depolymerization of actin in response to Ca2+ influx may serve as a feedback mechanism to attenuate potentially toxic levels of Ca2+ influx."( Evidence that actin depolymerization protects hippocampal neurons against excitotoxicity by stabilizing [Ca2+]i.
Furukawa, K; Mattson, MP; Smith-Swintosky, VL, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" In addition, the results of a clonogenic dose-response study on jasplakinolide are presented."( Biostructural features of additional jasplakinolide (jaspamide) analogues.
Amagata, T; Bray, WM; Crews, P; Gassner, NC; Lokey, RS; Media, J; Morinaka, BI; Robinson, SJ; Tenney, K; Valeriote, FA; Watts, KR, 2011
)
0.88
" The sensitivity of the high-throughput cell mechanical measurements to the cytoskeletal modifications we present in this study opens up new possibilities for label-free dose-response assays of cytoskeletal modifications."( High-throughput cell mechanical phenotyping for label-free titration assays of cytoskeletal modifications.
Golfier, S; Guck, J; Herbig, M; Mietke, A; Otto, O; Rosendahl, P, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
actin polymerisation inducerAny substance that induces the polymerisation of the protein actin.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID592492Anticancer activity against human IGROV1 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID224494In vitro inhibition of protein synthesis in tobacco mosaic virus mRNA-encoded proteins in rabbit reticulocyte lysate2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Inhibition of protein synthesis by didemnins: cell potency and SAR.
AID485982Growth inhibition of human HOP62 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485984Growth inhibition of human HCT15 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID318601Cytotoxicity against mouse P388 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID1604326Antiparasitic activity against Toxoplasma gondii infected in human HFF cells after 7 days by crystal violet assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
AID485988Growth inhibition of human 786-0 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID335488Effect on actin cytoskeleton in rat kangaroo PtK2 cells assessed as retracted cytoplasm and spiky appearance at 3 uM after 24 hrs by immunofluorescence analysis2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID771587Antiparasitic activity against Toxoplasma gondii expressing beta-galactosidase infected in HFF assessed as parasite growth inhibition treated for 2 hrs followed by washout measured after 48 hrs after 72 hrs relative to continuous culture in presence of dr2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
AID592431Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.1 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID335489Stimulation of rabbit muscle actin polymerization by centrifugation assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID592499Antimicrofilament activity in human HCT116 cells assessed as complete loss of microfilament network at 0.01 uM to 5 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID337554Antifungal activity against Candida albicans at <= 1 ug after 16 to 19 hrs by disk diffusion assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Screening of marine invertebrates for the presence of ergosterol-sensitive antifungal compounds.
AID592425Growth inhibition against human TSU-Pr1 cells assessed as disruption of actin cytoskeleton2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID1296043Cytotoxicity against human ONS cells derived from parkinsons disease patients assessed as alteration of cellular parameters at 10 uM2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID485990Growth inhibition of human RPMI8266 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID592515Antimicrofilament activity in human HCT116 cells assessed as total loss of microfilament network at 5 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592510Antimicrofilament activity in human HCT116 cells assessed as total loss of microfilament network at 1 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592500Cytotoxicity against human HCT116 cells assessed as time required to kill 90% of tumor cells at 0.004 uM by clonogenic assay2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485989Growth inhibition of human MCF7 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID592427Anticancer activity against human HCT116 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485981Cytotoxicity against human HeLa cells at 80 nM after 34 hrs by microfilament disruption assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID592498Cytotoxicity against human HCT116 cells assessed as time required to kill 90% of tumor cells by clonogenic assay2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID771592Antiparasitic activity against Toxoplasma gondii expressing beta-galactosidase infected in HFF assessed as parasite growth inhibition after 72 hrs2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
AID1296042Cytotoxicity against human ONS cells derived from parkinsons disease patients assessed as alteration of nuclear parameters at 10 uM2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID335485Effect on actin cytoskeleton in rat kangaroo PtK2 cells assessed as reorganization and hypernucleation of actin assembly at 0.03 uM after 24 hrs by immunofluorescence analysis2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID333092Effect on cell morphology in rat A10 cells assessed as actin aggregation at 23 nM by immunofluorescence assay2004Journal of natural products, Aug, Volume: 67, Issue:8
Synthesis, conformational analysis, and cytotoxicity of new analogues of the natural cyclodepsipeptide jaspamide.
AID335482Effect on actin cytoskeleton in rat kangaroo PtK2 cells assessed as increase in binucleated cells at 1 to 10 uM after 24 hrs by by immunofluorescence analysis2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID592493Anticancer activity against human U251 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485985Growth inhibition of human SF539 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID335219Antiproliferative activity against rat kangaroo PtK2 cells after 48 hrs2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID592495Anticancer activity against human DU145 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592511Antimicrofilament activity in human HCT116 cells assessed as total loss of microfilament network at 0.5 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID771591Cytotoxicity against HFF after 72 hrs2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
AID592430Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.01 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485987Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID337556Antifungal activity against Candida albicans at 5 ug after 16 to 19 hrs by disk diffusion assay in presence of 120 ppm ergosterol1993Journal of natural products, Jan, Volume: 56, Issue:1
Screening of marine invertebrates for the presence of ergosterol-sensitive antifungal compounds.
AID592424Growth inhibition against human LNCAP cells assessed as disruption of actin cytoskeleton2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592497Anticancer activity against human LOXIMVI cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID771590Induction of Toxoplasma gondii N-terminally his-tagged recombinant actin polymerization after 1 hr2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
AID1073067Antimicrobial activity against Candida albicans2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Scrutinizing the scaffolds of marine biosynthetics from different source organisms: Gram-negative cultured bacterial products enter center stage.
AID592494Anticancer activity against human NCI-H522 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID378714Cytotoxicity against human NSCLC-N6 cells by MTT assay1999Journal of natural products, Feb, Volume: 62, Issue:2
New jaspamide derivatives from the marine sponge Jaspis splendans collected in Vanuatu.
AID502146Growth inhibition of human CA46 cells assessed as induction of actin assembly after 24 hrs2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and biological evaluation of new jasplakinolide (jaspamide) analogs.
AID592429Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.05 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592428Anticancer activity against human MDA-MB-231 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID335490Stimulation of rabbit muscle actin polymerization assessed as light scattering at 10 to 50 uM by fluorimetry2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID337553Antifungal activity against Candida albicans after 16 to 19 hrs by disk diffusion assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Screening of marine invertebrates for the presence of ergosterol-sensitive antifungal compounds.
AID666463Inhibition of cell proliferation of human KB cells at 1 uM after 72 hrs by CellTiter 96 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID333091Effect on cell morphology in rat A10 cells assessed as actin aggregation at 0.85 nM by immunofluorescence assay2004Journal of natural products, Aug, Volume: 67, Issue:8
Synthesis, conformational analysis, and cytotoxicity of new analogues of the natural cyclodepsipeptide jaspamide.
AID592423Growth inhibition against human PC3 cells assessed as disruption of actin cytoskeleton2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485986Growth inhibition of human M14 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485983Growth inhibition of human HCT116 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID666462Inhibition of cell proliferation of human KB cells at 10 uM after 72 hrs by CellTiter assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID666464Growth inhibition of human KB cells after 72 hrs by CellTiter 96 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID335218Antiproliferative activity against human CA46 cells after 24 hrs2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID592496Anticancer activity against human A498 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID335481Effect on actin cytoskeleton in rat kangaroo PtK2 cells assessed as increase in binucleated cells at 0.3 to 3 uM after 24 hrs by immunofluorescence analysis2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
AID335492Displacement of FITC-phalloidin from rabbit muscle actin polymer after 1 hr by fluorescence analysis2002Journal of natural products, Jun, Volume: 65, Issue:6
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (405)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.25)18.7374
1990's35 (8.64)18.2507
2000's221 (54.57)29.6817
2010's138 (34.07)24.3611
2020's10 (2.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.21 (24.57)
Research Supply Index6.02 (2.92)
Research Growth Index6.85 (4.65)
Search Engine Demand Index54.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other403 (97.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]